Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging

American Journal of Neuroradiology

Volumn 26, Issue 2, 2005, Pages 266-273

  Cha, Soonmee ^a   Tihan, Tarik ^a   Crawford, Forrest ^a   Fischbein, Nancy J ^a   Chang, Susan ^a   Bollen, Andrew ^a   Nelson, S J ^a   Prados, Michael ^a   Berger, Mitchel S ^a   Dillon, William P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD VOLUME; BRAIN BLOOD VOLUME; CANCER GRADING; CANCER INFILTRATION; CANCER SURGERY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR VASCULARIZATION;

ADULT; AGED; BLOOD VOLUME; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA;

EID: 27944439436     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lopes M, Laws EJ. Low-grade central nervous system tumors. Neurosurg Focus 2002;12:1-4
2. Sasaki H, Zlatescu MC, Betensky RA, et al. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 2002; 61:58-63
3. van den Bent M. New perspectives for the diagnosis and treatment of oligodendroglioma. Expert Rev Anticancer Ther 2001;1:348-356
4. Pomper MG, Port JD. New techniques in MR imaging of brain tumors. Magn Reson Imaging Clin N Am 2000;8:691-713
5. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51
6. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211: 791-798
7. Sugahara T, Korogi Y, Koehi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479-1486
8. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6:2189-2200
9. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJNR Am J Neuroradiol 2004;25:214-221
10. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887
11. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79:1381-1393
12. Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 1999;277: R1218-1229
13. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncol 2000;2:45-59
14. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003;65:37-48
15. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol 2000;27:1-10
16. Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg 2001;94:978-984
17. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 2000;5:D213-231
18. Fathallah-Shaykh HM, Zhao LJ, Mickey B, Kafrouni AI. Molecular advances to treat cancer of the brain. Expert Opin Investig Drugs 2000;9:1207-1215
19. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479
20. Bogler O, Huang HJ, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995;15:308-327
21. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-645
22. Mineura K, Shioya H, Kowada M, Ogawa T, Hatazawa J, Uemura K. Blood flow and metabolism of oligodendrogliomas: a positron emission tomography study with kinetic analysis of 18F-fluorodeoxyglucose. J Neurooncol 1999;43:49-57
23. Christov C, Gherardi RK. Vascular endothelial growth factor (VEGF) likely contributes to oligodendroglioma angiogenesis. Acta Neuropathol (Berl) 1999;97:429-432
24. Varlet P, Guillamo JS, Nataf F, Koziak M, Beuvon F, Daumas-Duport C. Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 2000;26:379-389
25. Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 1998;24:29-35
26. Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001;92:165-171
27. Schiffer D, Bosone I, Dutto A, Di Vito N, Chio A. The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neurooncol 1999;44:99-107
28. Schiffer D, Dutto A, Cavalla P, et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997;24:313-319
29. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE. Oligodendroglioma: histologic evaluation and prognosis. J Neuropathol Exp Neurol 1986;45:65-78